Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT
Top Cited Papers
Open Access
- 17 May 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Computational Biology
- Vol. 8 (5), e1002518
- https://doi.org/10.1371/journal.pcbi.1002518
Abstract
Development of high throughput analytical methods has given physicians the potential access to extensive and patient-specific data sets, such as gene sequences, gene expression profiles or metabolite footprints. This opens for a new approach in health care, which is both personalized and based on system-level analysis. Genome-scale metabolic networks provide a mechanistic description of the relationships between different genes, which is valuable for the analysis and interpretation of large experimental data-sets. Here we describe the generation of genome-scale active metabolic networks for 69 different cell types and 16 cancer types using the INIT (Integrative Network Inference for Tissues) algorithm. The INIT algorithm uses cell type specific information about protein abundances contained in the Human Proteome Atlas as the main source of evidence. The generated models constitute the first step towards establishing a Human Metabolic Atlas, which will be a comprehensive description (accessible online) of the metabolism of different human cell types, and will allow for tissue-level and organism-level simulations in order to achieve a better understanding of complex diseases. A comparative analysis between the active metabolic networks of cancer types and healthy cell types allowed for identification of cancer-specific metabolic features that constitute generic potential drug targets for cancer treatment. Many serious diseases have a strong metabolic component. The abnormal metabolic states of diseased cells could therefore be targets for treatment. However, metabolism is a highly complex and interconnected system in which thousands of metabolic reactions occur simultaneously in any given cell type. In order to understand how metabolism of a diseased cell differs from its healthy counterpart we must therefore study the system as a whole. We have developed an algorithm that integrates several types of data in order to generate active metabolic networks; catalogues of the metabolic reactions that are likely to be active in a given cell type. We applied this algorithm to data for 69 healthy cell types and 16 cancer cell types. These metabolic networks can form the basis for simulation of metabolic interactions between organs or as scaffolds for interpretation of high-throughput data. We used these networks to perform an analysis between cancer and healthy cell types in order to identify cancer specific metabolic features that constitute potential drug targets. Several of the resulting targets were already known and used clinically, but we also found high-ranking reactions and metabolites which have not yet been investigated as drug targets.Keywords
This publication has 43 references indexed in Scilit:
- Cyclooxygenases and lipoxygenases in cancerCancer and Metastasis Reviews, 2011
- Fifteen years of large scale metabolic modeling of yeast: Developments and impactsBiotechnology Advances, 2011
- iAB-RBC-283: A proteomically derived knowledge-base of erythrocyte metabolism that can be used to simulate its physiological and patho-physiological statesBMC Systems Biology, 2011
- Pharmaceutical interventions for obesity: a public health perspectiveDiabetes, Obesity and Metabolism, 2011
- Otto Warburg's contributions to current concepts of cancer metabolismNature Reviews Cancer, 2011
- Predicting selective drug targets in cancer through metabolic networksMolecular Systems Biology, 2011
- The BRENDA Tissue Ontology (BTO): the first all-integrating ontology of all organisms for enzyme sourcesNucleic Acids Research, 2010
- Geranylgeranyl diphosphate depletion inhibits breast cancer cell migrationInvestigational New Drugs, 2010
- [Methylglyoxal--test for biological dysfunctions of homeostasis and endoecology, low cytosolic glucose level, and gluconeogenesis from fatty acids].2010
- Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studiesOncogene, 2000